Terms: = Prostate cancer AND ENO2, HEL-S-279, NSE AND Diagnosis
30 results:
1. Relevance of blood tumor markers in inpatients with significant involuntary weight loss and elevated levels of inflammation biomarkers.
Gronnier M; Hedhli K; Sauzay C; Salle V; Duhaut P; Schmidt J; Dernoncourt A
BMC Cancer; 2024 Apr; 24(1):468. PubMed ID: 38622530
[TBL] [Abstract] [Full Text] [Related]
2. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
3. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
4. Recent Progress in Biosensors for Detection of Tumor Biomarkers.
Li M; Jiang F; Xue L; Peng C; Shi Z; Zhang Z; Li J; Pan Y; Wang X; Feng C; Qiao D; Chen Z; Luo Q; Chen X
Molecules; 2022 Oct; 27(21):. PubMed ID: 36364157
[TBL] [Abstract] [Full Text] [Related]
5. Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis.
Kannan A; Clouston D; Frydenberg M; Ilic D; Karim MN; Evans SM; Toivanen R; Risbridger GP; Taylor RA
BJU Int; 2022 Oct; 130(4):420-433. PubMed ID: 34784097
[TBL] [Abstract] [Full Text] [Related]
6. Multiplex measurement of twelve tumor markers using a GMR multi-biomarker immunoassay biosensor.
Gao Y; Huo W; Zhang L; Lian J; Tao W; Song C; Tang J; Shi S; Gao Y
Biosens Bioelectron; 2019 Jan; 123():204-210. PubMed ID: 30174274
[TBL] [Abstract] [Full Text] [Related]
7. The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature.
Muoio B; Pascale M; Roggero E
Int J Biol Markers; 2018 Jan; 33(1):10-21. PubMed ID: 28885659
[TBL] [Abstract] [Full Text] [Related]
8. [SMALL CELL CARCINOMA OF THE prostate: A CASE REPORT OF RELATIVE LONG-TERM SURVIVAL].
Hirai M; Konishi T; Saito K; Washino S; Kobayashi Y; Nokubi M; Miyagawa T
Nihon Hinyokika Gakkai Zasshi; 2015 Oct; 106(4):280-4. PubMed ID: 26717788
[TBL] [Abstract] [Full Text] [Related]
9. [Small cell carcinoma of the prostate effectively treated for relatively long term: a case report].
Horie K; Kameyama K; Mizutani K; Sugawara T; Seike K; Tsuchiya T; Yasuda M; Yokoi S; Nakano M; Deguchi T; Suzui N; Hirose Y
Hinyokika Kiyo; 2014 Oct; 60(10):517-21. PubMed ID: 25391785
[TBL] [Abstract] [Full Text] [Related]
10. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.
Nolen BM; Brand RE; Prosser D; Velikokhatnaya L; Allen PJ; Zeh HJ; Grizzle WE; Huang Y; Lomakin A; Lokshin AE
PLoS One; 2014; 9(4):e94928. PubMed ID: 24747429
[TBL] [Abstract] [Full Text] [Related]
11. Clinical management of small-cell carcinoma of the urinary tract: a 10-year single-center's experience.
Carranza OE; Castañón E; Abella LE; Zudaire ME; Castillo A; Arévalo E; Fusco JP; Zudaire JJ; Carías R; Cambeiro M; Martínez-Monge R; Gil-Bazo I
Clin Genitourin Cancer; 2013 Jun; 11(2):168-74. PubMed ID: 23146567
[TBL] [Abstract] [Full Text] [Related]
12. [Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site].
Pejcić I; Vrbić S; Filipović S; Sćekić M; Petković I; Pejcić L; Djenić N
Vojnosanit Pregl; 2010 Sep; 67(9):723-31. PubMed ID: 20954411
[TBL] [Abstract] [Full Text] [Related]
13. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report].
Segawa N; Inamoto T; Ibuki N; Mizutani Y; Azuma H; Tsuji M; Katsuoka Y
Hinyokika Kiyo; 2010 Jan; 56(1):49-54. PubMed ID: 20104011
[TBL] [Abstract] [Full Text] [Related]
14. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract] [Full Text] [Related]
15. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract] [Full Text] [Related]
16. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184
[TBL] [Abstract] [Full Text] [Related]
17. [Prostatic carcinoma that arose with hearing loss: a case report].
Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
Hinyokika Kiyo; 2007 Jun; 53(6):413-6. PubMed ID: 17628942
[TBL] [Abstract] [Full Text] [Related]
18. [Small cell carcinoma of the prostate: a report of three patients and a prognostic analysis of cases reported in Japan].
Kageyama S; Narita M; Kim CJ; Hanada E; Sakano Y; Iwaki H; Yoshiki T; Okada Y
Hinyokika Kiyo; 2006 Oct; 52(10):809-15. PubMed ID: 17131874
[TBL] [Abstract] [Full Text] [Related]
19. [Clinical usefulness of circulating tumor markers].
Ohkura H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600
[TBL] [Abstract] [Full Text] [Related]
20. [Neuroendocrine cancer of the prostate. A series of 6 cases].
Breton X; Plazanet C; Murat FJ; Milinkevitch S; Irani J; Levillain P; Doré B
Prog Urol; 2003 Dec; 13(6):1340-4. PubMed ID: 15000310
[TBL] [Abstract] [Full Text] [Related]
[Next]
